ISSN: 2155-6105

Zeitschrift für Suchtforschung und -therapie

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Indiziert in
  • CAS-Quellenindex (CASSI)
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Öffnen Sie das J-Tor
  • Genamics JournalSeek
  • Akademische Schlüssel
  • JournalTOCs
  • SafetyLit
  • Nationale Wissensinfrastruktur Chinas (CNKI)
  • Elektronische Zeitschriftenbibliothek
  • RefSeek
  • Hamdard-Universität
  • EBSCO AZ
  • OCLC – WorldCat
  • SWB Online-Katalog
  • Virtuelle Bibliothek für Biologie (vifabio)
  • Publons
  • Genfer Stiftung für medizinische Ausbildung und Forschung
  • Euro-Pub
  • ICMJE
Teile diese Seite

Abstrakt

A Descriptive Review of Hyperbaric Oxygen Therapy in the Management of Substance Use Disorders

Peter McCann and Margaret-Ann McCann

Background and aim: Psychological therapies and some limited pharmacotherapy forms the mainstay of treatment for substance use disorders. However despite extensive research little progress has been made into developing therapies to aid in the initial detoxification phase, the maintenance of remission and to treat the morbidity associated with many drugs of abuse. The following review explores the use of hyperbaric oxygen therapy as an adjunctive treatment for some of the harmful aspects of exposure to alcohol, cocaine and opioids. Method: We conducted a systematic review of articles searched through PubMed for the use of HBOT for conditions related to alcohol, cocaine and opioid use disorders. Outcome measures included improvement in neurocognitive functioning, improvement in withdrawal symptoms and improved sleep and quality of life. Results: Few studies directly investigated the use of HBOT for complications of substance use in humans however several studies were found that looked at conditions with shared features including traumatic brain injury, vascular dementia and chronic pain. Conclusion: There is a lack of human studies assessing the impact of HBOT on sequelae of substance use however findings from animal studies and use of HBOT in related conditions show that there is potential for this therapy in the management of withdrawal syndromes, neurocognitive deficits and quality of life.